Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction

Transplantation

Volumn 63, Issue 10, 1997, Pages 1508-1514

  Casiraghi, Federica ^a   Ruggenenti, Piero ^a,b   Noris, Marina ^a   Locatelli, Giuseppe ^b   Perico, Norberto ^a,b   Perna, Annalisa ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; HLA ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3; STEROID;

ADULT; ARTICLE; BLOOD LEVEL; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY DISEASE; MALE; MONITORING; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; URINARY EXCRETION; URINE;

ACUTE DISEASE; ADULT; FEMALE; GRAFT REJECTION; HUMANS; INTERLEUKIN-6; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; SOLUBILITY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; URINE;

EID: 0030949082     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199705270-00023     Document Type: Article

References (43)

1. Lindholm A, Ohlman S, Albrecitsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by three cyclosporine regimens. Transplantation 1993; 56: 307.
2. Wilczek HE. Percutaneous needle biopsy of the renal allograft. Transplantation 1990; 50: 790.
3. Huraib S, Goldberg H, Kate A, et al. Percutaneous needle biopsy of the transplanted kidney: technique and complications. Am J Kidney Dis 1989; 14: 13.
4. Tisher CC. Clinical indications for kidney biopsy. In: Tisher CC, Brenner BM, eds. Renal pathology with clinical and functional correlations. Philadelphia: JB Lippincott Co., 1994: 75.
5. Chan GLC, Hodge EE, Chang HHH. The use of routinely available clinical data in differentiating renal allograft rejection from cyclosporine nephrotoxicity. Transplantation 1989; 48: 1075.
6. Milford EL, Hancock W, Carpenter CB. Immunopathogenetic mechanisms of allograft rejection. In: Tisher CC, Brenner BM, eds. Renal pathology with clinical and functional correlations. Philadelphia: JB Lippincott Co., 1994: 1581.
7. Yoshimura N, Oka T, Kahan BD. Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991; 51: 172.
8. Van Oers MHJ, Van Der Heyden AAPAM, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71: 314.
9. Simpson MA, Madras PN, Cornaby AJ, et al. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989; 47: 218.
10. Schroeder TJ, Helling T, McKenna RM, et al. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients. Transplantation 1992; 53: 34.
11. Bock GH, Neu L, Long C, et al. An assessment of serum and urine soluble interleukin-2 receptor concentrations during renal transplant rejection. Am J Kidney Dis 1994; 23: 421.
12. Manfro RC, Pohanka SJ, Tomlanovich SJ, Benet LZ, Salvatierra O Jr, Garovoy MR. Determination of soluble IL-2 receptors in kidney graft recipients: a 6-month follow-up. Transplant Proc 1990; 22: 1861.
13. Plaza JJ, Blum G, Ortiz A, et al. Usefulness of serum interleukin 2 receptor levels in renal allograft recipients. Transplant Proc 1992; 24: 63.
14. Magalini SC, Nanni G, Tacchino RM, Avolio AW, Castagneto M. Lack of predictivity of serum neopterin, soluble interleukin-2 receptor and serum amyloid A in long-term kidney transplant recipients. Transplant Proc 1992; 24: 2547.
15. Newstead CG, Lamb WR, Brenchley PEC, Short CD. Serum and urine IL-6 and TNF-α in renal transplant recipients with graft dysfunction. Transplantation 1993; 56: 831.
16. Kutukculer N, Clark K, Rigg KM, et al. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients. Transplantation 1995; 59: 333.
17. Trochu JN, Denis M, Auget JL, et al. Soluble interleukin 2 receptor (Tac chain) is not a reliable marker in kidney transplant recipient monitoring. Transpl Int 1992; 5: 145.
18. Montagnino C, Tarantino A, Grignani S, Braga M, Ponticelli C. Soluble interleukin-2 receptor (sIL-2R) levels in renal transplantation: comparison between clinical and laboratory analysis. Clin Transplant 1995; 9: 25.
19. Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Annu Rev Immunol 1986; 4: 119.
20. Simpson MA, Madras PN, Cornaby AJ, Dempsey RA, Monaco AP. Origin of elevated IL-2 and IL-2R in the urine of rejecting renal allograft recipients. Transplant Proc 1989; 21: 299.
21. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619.
22. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. The molecular basis for the generation of the human soluble interleukin-2 receptor. Cytokine 1990; 2: 330.
23. Marcon L, Fritz ME, Kurman CC, Jensen JC, Nelson DL. Soluble Tac peptide is present in the urine of normal individuals and elevated levels in patients with adult T cell leukemia. Clin Exp Immunol 1988; 73: 29.
24. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokine: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860.
25. Garman RD, Jacobs KA, Clark SC, Raulet DH. B cell stimulatory factor 2 (β2 interferon) functions as a second signal for interleukin-2 production by mature murine T cells. Proc Natl Acad Sci USA 1987; 84: 7629.
26. Hirano T, Taga T, Yasukawa K, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987; 84: 228.
27. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF of BSFp-2). Proc Natl Acad Sci USA 1985; 82: 5490.
28. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induce B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73.
29. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol 1988; 6: 485.
30. Holsti MA, Raulet DH. IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells. J Immunol 1989; 143: 2514.
31. Okada M, Kitahana M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF2 functions as a killer helper factor in the in vitro induction of cytotoxic T-cells. J Immunol 1988; 141: 1543.
32. Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56.
33. Gotti E, Casiraghi F, Noris M, Benigni A, Remuzzi G. Enhanced urinary interleukin-6 (IL-6) and interleukin-1 β (IL-1 β) parallel renal disease activity in systemic lupus erythematosus (SLE) [Abstract]. J Am Soc Nephrol 1994; 5: 749.
34. SAS Institute Inc. SAS/Stat user's guide, version 6 (4th ed). Cary, NC: SAS Institute Inc., 1989.
35. Hancock WW, Gee D, De-Moerloose P, Rickles FR, Ewan VA, Atkins RC. Immunohistological analysis of serial biopsies taken during human renal allograft rejection: changing profile of infiltrating cells and activation of the coagulation system. Transplantation 1985; 39: 430.
36. Von Willebrand E, Salmela K, Isoniemi H, Krogerus L, Taskinen E, Hayry P. Induction of HLA class II antigen and interleukin 2 receptor expression in acute vascular rejection of human kidney allografts. Transplantation 1992; 53: 1077.
37. Kooijmans-Coutinho MF, Bruijn JA, Hermans J, et al. Evaluation by histology, immunohistology and PCR of protocollized renal biopsies 1 week post-transplant in relation to subsequent rejection episodes. Nephrol Dial Transplant 1995; 10: 847.
38. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860.
39. Raasveld MHM, Weening JJ, Kerst JM, Surachno S, ten Berge RJM. Local production of interleukin-6 during acute rejection in human renal allografts. Nephrol Dial Transplant 1993; 8: 75.
40. Vandenbroecke C, Caillat-Zucman S, Legendre C, et al. Differential in situ expression of cytokines in renal allograft rejection. Transplantation 1991; 51: 602.
41. Merville P, Pouteil-Noble C, Wijdenes J, et al. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversible rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation 1993; 55: 639.
42. Blancho G, Moreau JF, Chabannes D, Chatenoud L, Soulillou JP. HILDA/LIF, G-CSF, IL-1β, IL-6, and TNFα production during acute rejection of human kidney allografts. Transplantation 1993; 56: 597.
43. Shield CF III, Jacobs RJ, Wyant S, Das A. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 1996; 27: 855.